SCHEMBL18154372

SCHEMBL18154372

CC(C)(NC(=O)C(N)Cc1ccccc1)C(=O)Nc1nc2ccc(OC(F)(F)F)cc2s1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
DYRK1A Q13627 1/20 0.58
ACP1 P24666 1/20 0.55
CSNK1D P48730 5/20 0.53
CSNK2A2 P19784 1/20 0.51
CSNK2B P67870 1/20 0.51
CSNK2A1 P68400 1/20 0.51
CSNK2A3 Q8NEV1 1/20 0.51
HDAC3 O15379 1/20 0.49
HDAC4 P56524 1/20 0.49
HDAC1 Q13547 1/20 0.49
HDAC7 Q8WUI4 1/20 0.49
HDAC2 Q92769 1/20 0.49
HDAC10 Q969S8 1/20 0.49
HDAC11 Q96DB2 1/20 0.49
HDAC8 Q9BY41 1/20 0.49
HDAC6 Q9UBN7 1/20 0.49
HDAC9 Q9UKV0 1/20 0.49
HDAC5 Q9UQL6 1/20 0.49
WNT3A P56704 1/20 0.47
CASR P41180 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18154170 1.00 DYRK1A (0.58) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
SCHEMBL30794512 1.00 DYRK1A (0.58) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
SCHEMBL18154420 0.90 DYRK1A (0.52) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
SCHEMBL18154485 0.90 DYRK1A (0.52) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
SCHEMBL30796534 0.90 DYRK1A (0.52) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
SCHEMBL16445348 0.89 ACP1 (0.65) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
SCHEMBL16445023 0.89 ACP1 (0.65) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
SCHEMBL16445025 0.89 ACP1 (0.65) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
Hydrochloric Acid SCHEMBL31442239 0.89 ACP1 (0.64) DYRK1AACP1CSNK1DCSNK2A2CSNK2B
Hydrochloric Acid SCHEMBL18154121 0.89 ACP1 (0.64) DYRK1AACP1CSNK1DCSNK2A2CSNK2B

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 31 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-04-02 US claimed
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-02-12 US claimed
US-20180037557-A1 PRODRUGS RILUZOLE AND THEIR METHOD OF USE BEETLEJUICE SA LLC, AS PURCHASER AGENT 2018-02-08 US claimed
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-04-02 US disclosed
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE BIOHAVEN THERAPEUTICS LTD (US) 2026-02-12 US disclosed
US-12472165-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-11-18 US disclosed
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN THERAPEUTICS LTD (US) 2025-10-30 US disclosed
US-12295942-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-05-13 US disclosed
US-12213965-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (VG) 2025-02-04 US disclosed
US-12005046-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2024-06-11 US disclosed
US-12005047-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2024-06-11 US disclosed
US-11052070-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2021-07-06 US disclosed
CN-107567438-B Riluzole prodrugs and uses thereof 拜尔哈文制药股份有限公司 2021-06-29 CN disclosed
US-10905681-B2 Riluzole prodrugs and their use BIOHAVEN THERAPEUTICS LTD. (US) 2021-02-02 US disclosed
US-20200289475-A1 RILUZOLE PRODRUGS AND THEIR USE BEETLEJUICE SA LLC, AS PURCHASER AGENT 2020-09-17 US disclosed
US-10639298-B2 Prodrugs of riluzole and their method of use BIOHAVEN THERAPEUTICS LTD. (US) 2020-05-05 US disclosed
US-20200085794-A1 RILUZOLE PRODRUGS AND THEIR USE BIOHAVEN THERAPEUTICS LTD. (JP) 2020-03-19 US disclosed
US-20180037557-A1 PRODRUGS RILUZOLE AND THEIR METHOD OF USE BEETLEJUICE SA LLC, AS PURCHASER AGENT 2018-02-08 US disclosed
US-20180036290-A1 RILUZOLE PRODRUGS AND THEIR USE BEETLEJUICE SA LLC, AS PURCHASER AGENT 2018-02-08 US disclosed
WO-2016140878-A9 PRODRUGS RILUZOLE AND THEIR METHOD OF USE BIOHAVEN PHARMACEUTICAL HOLDING COMPANY LTD. (US) 2016-10-20 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (15 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10905681-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-20200289475-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-20180036290-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-20260091024-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE IL6ST, GFRA3, GFRA1 DYRK1A 3529/4885ACP1 1494/4885CSNK1D 382/4885
US-12005046-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-12005047-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-20260041673-A1 PRODRUGS OF RILUZOLE AND THEIR METHOD OF USE GFRA3, IL6ST, GFRA1 DYRK1A 3599/4885ACP1 1469/4885CSNK1D 404/4885
US-12472165-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-11052070-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-12295942-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-20180037557-A1 PRODRUGS RILUZOLE AND THEIR METHOD OF USE APEH, CYP2C9, ALDH1A2 DYRK1A 3736/4885ACP1 1159/4885CSNK1D 1728/4885
US-20250332148-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-20200085794-A1 RILUZOLE PRODRUGS AND THEIR USE APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-12213965-B2 Riluzole prodrugs and their use APEH, ALDH1A2, UGT1A9 DYRK1A 3818/4885ACP1 1068/4885CSNK1D 1699/4885
US-10639298-B2 Prodrugs of riluzole and their method of use APEH, UGT1A9, ALDH3A1 DYRK1A 3437/4885ACP1 932/4885CSNK1D 1707/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.